Current Pharmaceutical Design

Src Inhibitors and Angiogenesis
pp. 2118-2128(11)
Authors: S. Schenone; F. Manetti; M. Botta

Targeting Vascular Cell Migration as a Strategy for Blocking Angiogenesis: The Central Role of Focal Adhesion Protein Tyrosine Kinase Family
pp. 2129-2145(17)
Authors: A. Angelucci; M. Bologna

Editorial [Hot Topic: New Potential Pharmaceutical Targets of Metabolic Syndrome (Executive Editors: Gianluca Iacobellis and Giuseppe Barbaro)]
pp. 2146-2147(2)
Authors: Gianluca Iacobellis; Giuseppe Barbaro

Metabolic Syndrome and Adipose Tissue: New Clinical Aspects and Therapeutic Targets
pp. 2148-2168(21)
Authors: C.V. Iannucci; D. Capoccia; M. Calabria; F. Leonetti

Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
pp. 2169-2175(7)
Authors: Amaia Rodriguez; Victoria Catalan; Javier Gomez-Ambrosi; Gema Fruhbeck

Homo obesus: A Metabotrophin-Deficient Species. Pharmacology and Nutrition Insight
pp. 2176-2179(4)
Authors: G.N. Chaldakov; M. Fiore; A.B. Tonchev; D. Dimitrov; R. Pancheva; G. Rancic; L. Aloe

Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome
pp. 2180-2184(5)
Authors: Gianluca Iacobellis; Arya M. Sharma

Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
pp. 2185-2192(8)
Author: Yu-Jing Gao

Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
pp. 2193-2198(6)
Authors: Giuseppe Palasciano; Antonio Moschetta; Vincenzo O. Palmieri; Ignazio Grattagliano; Gianluca Iacobellis; Piero Portincasa

Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
pp. 2199-2207(9)
Authors: Michele Petruzzelli; Giuseppe Lo Sasso; Piero Portincasa; Giuseppe Palasciano; Antonio Moschetta

Visceral Fat as Target of Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome
pp. 2208-2213(6)
Author: Giuseppe Barbaro